Suggestions
Michael McCurdy
Chief Medical Officer, Miraki Innovation
Michael McCurdy, MD, is an accomplished medical professional with extensive experience in internal medicine, emergency medicine, and critical care medicine. Dr. McCurdy earned his Bachelor's degree, magna cum laude, from the University of Notre Dame before going on to complete his medical studies at UT Health San Antonio. He then successfully completed his Internal Medicine Residency Program, Emergency Medicine Residency Program, and Critical Care Medicine Fellowship at the University of Maryland School of Medicine.
Dr. McCurdy has held several leadership positions throughout his career and currently serves as the Chief of the Department of Medicine and Chief of the Division of Critical Care Medicine at the University of Maryland St. Joseph Medical Center. He has also served as a Clinical Associate Professor, Associate Professor, and Assistant Professor at the University of Maryland School of Medicine. Dr. McCurdy has also provided clinical advisory services to BOA Biomedical, Nereus Medical Solutions, and ICmed LLC. He has been a member of several boards of advisors, including the St. Luke Foundation for Haiti.
Dr. McCurdy's expertise and experience in critical care medicine make him a valuable and knowledgeable resource in the medical field. He is dedicated to providing the highest level of care to his patients and is continuously seeking ways to improve medical practices in critical care medicine.
Highlights
As the CDC and WHO advocate for solutions to pressing global antimicrobial resistance (AMR) problems, two main solutions exist: 1) create more effective antimicrobials; and 2) minimize the use of existing antimicrobials. Creating more antimicrobials is an expensive Band-Aid that perpetuates our ongoing arms race against Mother Nature; however, rapidly and accurately identifying pathogens permits prompt microbe-specific treatment, thereby reducing unnecessary broad-spectrum antimicrobial use.
Our recently released publication highlights how utilizing the pathogen-binding protein FcMBL shortened the time to identification of a rare fungus in a neonate with cancer by 30 hours (!), as compared to an existing cutting-edge pathogen identification method.
A special thanks to my colleagues at BOA Biomedical, Harvard's Wyss Institute, Great Ormond Street Hospital, & University College London.
This newly released publication (https://lnkd.in/eUad9uVM) is particularly special, as it highlights the results of a very challenging 10-year focused effort by some of the most resilient, brilliant, kind, hardworking people I know. Establishing a sustainable surgical endeavor in a resource-limited environment is no small accomplishment, especially in one fraught with recurrent natural and manmade tragedy, yet the amazing medical personnel in Haiti led by Fr./Dr. Frechette (https://lnkd.in/ek3ME2mv) have done exactly that and more. Truly inspirational work that will only grow in Haiti and can be translated to other locations around the world, and I encourage all who have an interest in supporting these endeavors to explore the St. Luke Foundation website (https://lnkd.in/euKa88TG) to find out how to help.
